- Home
- ALHC vs CELC Comparison
ALHC vs CELC Comparison
Compare ALHC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALHC
- CELC
- Stock Information
- Founded
- ALHC 2013
- CELC 2011
- Country
- ALHC United States
- CELC United States
- Employees
- ALHC N/A
- CELC N/A
- Industry
- ALHC Medical Specialities
- CELC Medical Specialities
- Sector
- ALHC Health Care
- CELC Health Care
- Exchange
- ALHC Nasdaq
- CELC Nasdaq
- Market Cap
- ALHC 2.7B
- CELC 2.3B
- IPO Year
- ALHC 2021
- CELC 2017
- Fundamental
- Price
- ALHC $16.05
- CELC $49.42
- Analyst Decision
- ALHC Buy
- CELC Strong Buy
- Analyst Count
- ALHC 11
- CELC 6
- Target Price
- ALHC $18.14
- CELC $63.00
- AVG Volume (30 Days)
- ALHC 4.7M
- CELC 944.8K
- Earning Date
- ALHC 10-30-2025
- CELC 11-13-2025
- Dividend Yield
- ALHC N/A
- CELC N/A
- EPS Growth
- ALHC N/A
- CELC N/A
- EPS
- ALHC N/A
- CELC N/A
- Revenue
- ALHC $3,335,894,000.00
- CELC N/A
- Revenue This Year
- ALHC $47.18
- CELC N/A
- Revenue Next Year
- ALHC $28.47
- CELC N/A
- P/E Ratio
- ALHC N/A
- CELC N/A
- Revenue Growth
- ALHC 49.46
- CELC N/A
- 52 Week Low
- ALHC $9.15
- CELC $7.58
- 52 Week High
- ALHC $21.06
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- ALHC 44.43
- CELC 47.43
- Support Level
- ALHC $17.00
- CELC $49.82
- Resistance Level
- ALHC $17.69
- CELC $52.76
- Average True Range (ATR)
- ALHC 0.61
- CELC 3.06
- MACD
- ALHC -0.12
- CELC -1.34
- Stochastic Oscillator
- ALHC 8.87
- CELC 42.19
About ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.